BIVI (BioVie Inc.) Kacepetan wutah bathi saben saham ing taun lumaku

Simbol resmi perusahaan biovieinc.com (BIVI)

BioVie Inc. develops innovative therapies for severe liver pathologies and neurodegeneration. The annual earnings per share growth vector on the GURU.Markets chart confirms a trend where the value has stabilized at 0.00. However, the expansion of Alzheimer's and Parkinson's disease programs is increasing laboratory expenses. The brand's high scientific authority and the trust of clinics ensure the company maintains a stable position.

BIVI (BioVie Inc) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 14.11.2026

Rincian analitis lan laporan data perusahaan biovieinc.com (BIVI)

- rega saham lan konsensus proyeksi valuasi:
Bagan rega BioVie|BIVI - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Nilai pasar BIVI|BIVI - Nilai Total Perusahaan
- data ekuitas miturut neraca:
Nilai Akuntansi Saham BioVie|BIVI - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku biovieinc.com|BIVI - Total Aset Perusahaan
- rincian utang lan likuiditas:
Koefisien Total Utang marang Modal BioVie Inc.|BIVI - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal BioVie|BIVI - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku BIVI|BIVI - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak BioVie|Likuiditas darurat biovieinc.com
- indikator pendapatan resik lan kelipatan nilai:
BIVI - Penghasilan resik|Penghasilan resik sing dikarepake BioVie Inc.|BIVI - Pangali P/E|Kapitalisasi marang proyeksi bathi BioVie|BIVI - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan BIVI|BIVI - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan BioVie|BIVI - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan biovieinc.com|BIVI - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BioVie Inc.
- informasi babagan volume dodolan lan pendapatan:
BIVI - Pendapatan lan volume dodolan|Dodolan mangsa ngarep perusahaan BioVie|BIVI - Kapitalisasi marang pendapatan|Rasio rega marang prakiraan pendapatan BIVI
Ringkesan analisis perusahaan:BioVie Pharma, BIVI
Produk seri BioVie Inc.

BioVie Inc. focuses on the development of the innovative drug NE3107 to combat neuroinflammation in Alzheimer's and Parkinson's diseases. The commercialization efficiency of such developments directly impacts the net profit distributed per share. This metric measures the percentage deviation of the current EPS from the value of the same period last year. It allows for an assessment of the business's financial resilience to market shocks. By analyzing the shift in earnings per share compared to last year, an investor determines the company's profitability dynamics.

Pesaing langsung

ARWR (Arrowhead Pharma) - Wutah bathi saben saham ing taun lumaku|MIRM (Mirum Pharma) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku dynavax.com DVAX|Wutah bathi saben saham ing taun lumaku Arbutus Biopharma (ABUS)|IVA (inventivapharma.com) - Tambahing bathi saben saham ing taun lumaku|Wutah bathi ing taun lumaku GYRE (Gyre Therapeutics)|Assembly Bio - Wutah bathi saben saham ing taun lumaku|Galectin - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun iki Genfit S.A. GNFT|durect.com (DRRX) - Wutah bathi saben saham ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Aligos Therapeutics, Inc. (ALGS)|Wutah bathi resik saben saham ing taun iki GLMD|Wutah bathi saben saham ing taun lumaku NDRA|Wutah bathi ing taun lumaku HEPA